- Home
- BRTX vs MBRX Comparison
BRTX vs MBRX Comparison
Compare BRTX & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRTX | MBRX |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.1M |
| IPO Year | 2015 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BRTX | MBRX |
|---|---|---|
| Price | $0.30 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 3.5M | 115.9K |
| Earning Date | 03-26-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $81,000.00 | N/A |
| Revenue This Year | $24.64 | N/A |
| Revenue Next Year | $287.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.25 |
| 52 Week High | $2.04 | $7.98 |
Technical Indicators
Market Signals| Indicator | BRTX | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 47.07 |
| Support Level | $0.20 | $0.37 |
| Resistance Level | $1.18 | $5.15 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 80.48 | 82.76 |
Price Performance
Historical ComparisonAbout BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.